PH12018501318A1 - Polymorphic crystalline forms of obeticholic acid - Google Patents
Polymorphic crystalline forms of obeticholic acidInfo
- Publication number
- PH12018501318A1 PH12018501318A1 PH12018501318A PH12018501318A PH12018501318A1 PH 12018501318 A1 PH12018501318 A1 PH 12018501318A1 PH 12018501318 A PH12018501318 A PH 12018501318A PH 12018501318 A PH12018501318 A PH 12018501318A PH 12018501318 A1 PH12018501318 A1 PH 12018501318A1
- Authority
- PH
- Philippines
- Prior art keywords
- crystalline forms
- obeticholic acid
- polymorphic crystalline
- disease
- useful
- Prior art date
Links
- ZXERDUOLZKYMJM-ZWECCWDJSA-N obeticholic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)CCC(O)=O)CC[C@H]21 ZXERDUOLZKYMJM-ZWECCWDJSA-N 0.000 title abstract 3
- 229960001601 obeticholic acid Drugs 0.000 title abstract 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010008635 Cholestasis Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/979,005 US9982008B2 (en) | 2012-06-19 | 2015-12-22 | Preparation and uses of obeticholic acid |
| PCT/US2016/012651 WO2017111979A1 (en) | 2015-12-22 | 2016-01-08 | Polymorphic crystalline forms of obeticholic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12018501318A1 true PH12018501318A1 (en) | 2019-02-18 |
Family
ID=55650649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12018501318A PH12018501318A1 (en) | 2015-12-22 | 2018-06-20 | Polymorphic crystalline forms of obeticholic acid |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP3394081A1 (enExample) |
| JP (1) | JP2018538331A (enExample) |
| KR (1) | KR20180095070A (enExample) |
| CN (1) | CN108495858A (enExample) |
| AU (1) | AU2016375566A1 (enExample) |
| BR (1) | BR112018012590A2 (enExample) |
| CA (1) | CA3009149A1 (enExample) |
| CL (1) | CL2018001720A1 (enExample) |
| CO (1) | CO2018006701A2 (enExample) |
| EA (1) | EA201891491A1 (enExample) |
| IL (1) | IL259998A (enExample) |
| MX (1) | MX2018007776A (enExample) |
| PH (1) | PH12018501318A1 (enExample) |
| SG (1) | SG11201805235XA (enExample) |
| WO (1) | WO2017111979A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105801653B (zh) * | 2014-12-30 | 2018-04-17 | 苏州晶云药物科技有限公司 | 奥贝胆酸的晶型a及其制备方法 |
| WO2018211413A1 (en) * | 2017-05-15 | 2018-11-22 | Dr. Reddy’S Laboratories Limited | Solid forms of obeticholic acid and process for preparation |
| CN109280071A (zh) * | 2017-07-19 | 2019-01-29 | 东莞东阳光药物研发有限公司 | 奥贝胆酸的晶型及其制备方法 |
| CN107383139A (zh) * | 2017-08-09 | 2017-11-24 | 杭州和泽医药科技有限公司 | 一种3α‑羟基‑7‑氧代‑5β‑胆烷酸新衍生物制备奥贝胆酸的方法 |
| CZ31099U1 (cs) * | 2017-09-05 | 2017-10-17 | Zentiva, K.S. | Krystalické formy (3a,5B,6a,7a)-6-ethyl-3,7- dihydroxycholan-24-ové kyseliny |
| CN109485687A (zh) * | 2017-09-12 | 2019-03-19 | 成都弘达药业有限公司 | 奥贝胆酸的晶型j及其制备方法 |
| WO2019106043A1 (en) | 2017-11-29 | 2019-06-06 | Hexal Ag | Pharmaceutical composition comprising obeticholic acid |
| GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
| CN113264972B (zh) * | 2020-02-14 | 2024-07-12 | 四川科伦药物研究院有限公司 | 一种制备奥贝胆酸的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20050912A1 (it) * | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
| ES2822375T3 (es) * | 2012-06-19 | 2021-04-30 | Intercept Pharmaceuticals Inc | Preparación de la forma no cristalina del ácido obeticólico |
| CN106459136B (zh) * | 2014-09-28 | 2018-06-26 | 江苏盛迪医药有限公司 | 一种奥贝胆酸的制备方法 |
| TWI686400B (zh) * | 2014-11-19 | 2020-03-01 | 英商Ｎｚｐ英國有限公司 | 化合物（二） |
| MX375863B (es) * | 2014-11-19 | 2025-03-07 | Nzp Uk Ltd | Esteroides de 6-alquil-7-hidroxi-4-en-3-ona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr) |
| EA033603B1 (ru) * | 2014-11-19 | 2019-11-08 | Nzp Uk Ltd | 6-альфа-алкил-6,7-дионовые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr |
| CN107108688B (zh) * | 2014-11-19 | 2019-10-29 | Nzp英国有限公司 | 作为制备类固醇FXR调节剂的中间体的6α-烷基-3,7-二酮类固醇 |
-
2016
- 2016-01-08 EA EA201891491A patent/EA201891491A1/ru unknown
- 2016-01-08 EP EP16714049.0A patent/EP3394081A1/en not_active Withdrawn
- 2016-01-08 BR BR112018012590A patent/BR112018012590A2/pt not_active Application Discontinuation
- 2016-01-08 SG SG11201805235XA patent/SG11201805235XA/en unknown
- 2016-01-08 CN CN201680079793.8A patent/CN108495858A/zh active Pending
- 2016-01-08 KR KR1020187020850A patent/KR20180095070A/ko not_active Withdrawn
- 2016-01-08 MX MX2018007776A patent/MX2018007776A/es unknown
- 2016-01-08 WO PCT/US2016/012651 patent/WO2017111979A1/en not_active Ceased
- 2016-01-08 AU AU2016375566A patent/AU2016375566A1/en not_active Abandoned
- 2016-01-08 CA CA3009149A patent/CA3009149A1/en not_active Abandoned
- 2016-01-08 JP JP2018532396A patent/JP2018538331A/ja active Pending
-
2018
- 2018-06-13 IL IL259998A patent/IL259998A/en unknown
- 2018-06-20 PH PH12018501318A patent/PH12018501318A1/en unknown
- 2018-06-22 CL CL2018001720A patent/CL2018001720A1/es unknown
- 2018-06-27 CO CONC2018/0006701A patent/CO2018006701A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3394081A1 (en) | 2018-10-31 |
| EA201891491A1 (ru) | 2018-11-30 |
| BR112018012590A2 (pt) | 2018-12-04 |
| CN108495858A (zh) | 2018-09-04 |
| CL2018001720A1 (es) | 2018-08-10 |
| AU2016375566A1 (en) | 2018-07-05 |
| JP2018538331A (ja) | 2018-12-27 |
| SG11201805235XA (en) | 2018-07-30 |
| IL259998A (en) | 2018-07-31 |
| CO2018006701A2 (es) | 2018-07-10 |
| WO2017111979A1 (en) | 2017-06-29 |
| KR20180095070A (ko) | 2018-08-24 |
| MX2018007776A (es) | 2018-08-09 |
| CA3009149A1 (en) | 2017-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018501318A1 (en) | Polymorphic crystalline forms of obeticholic acid | |
| IN2014MN02561A (enExample) | ||
| HUS2200011I1 (hu) | Készítmények és eljárások HAO1 (hidroxisav-oxidáz-1 (glikolát-oxidáz)) gén expressziójának gátlására | |
| HRP20190270T1 (hr) | C1-inh pripravci i postupci za prevenciju i liječenje poremećaja povezanih s nedostatkom inhibitora c1 esteraze | |
| EP3174550A4 (en) | Methods and compositions relating to treatment of pulmonary arterial hypertension | |
| SMT202100325T1 (it) | Metodi e composizioni per l’inibizione specifica della glicolato ossidasi (hao1) mediante rna a doppio filamento | |
| GB2551964B (en) | Method of treating biomass to remove RNA | |
| DK3224234T3 (da) | Proces til fremstilling af estere af mælkesyre og 2-hydroxy-3-butensyre fra sukre | |
| MX2016015577A (es) | La teobromina o sus derivados para el tratamiento o la prevencion de la litiasis renal. | |
| EP3251675A4 (en) | Prevention or treatment of uric acid or gout disease | |
| EP3027180A4 (en) | Compositions and methods of the treatment of fatty acid metabolism disorders | |
| EP2857031A4 (en) | COMPOSITION FOR PREVENTING AND TREATING AIDS AND MANUFACTURING METHOD THEREFOR | |
| FR2994569B1 (fr) | Procede de fabrication de compositions riches en cristaux de mannitol sous forme delta, compositions et cristaux obtenus ainsi que leurs utilisations | |
| HK40058745B (zh) | 用於抑制hao1(羟酸氧化酶1(乙醇酸盐氧化酶))基因表达的组合物及方法 |